Uveitis Treatment Market | Global Demand and Trends 2025
Uveitis refers to an autoimmune eye disease that causes inflammation in the uvea of the eye. Uveitis is considered to be one of the leading cause of blindness in the U.S. According to the Ocular Immunology and Uveitis Foundation in 2016, Uveitis is the third leading cause of blindness in the U.S. having affecting approximately 38 cases per 100,000 population. The three common types of uveitis are anterior uveitis (swelling of the uvea towards the front of the eye), intermediate uveitis (swelling in the middle of the eye), and posterior uveitis (swelling of the uvea towards the back of the eye). Panuveitis refers to a case in which all three areas of the eye are affected by inflammation. The most common type among the three is the anterior uveitis.
To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/1094
Major factors driving growth of the global uveitis treatment market include rising incidence of uveitis and complications associated with the disease. According to a survey published in research journal of JAMA Ophthalmology, non-infectious uveitis was reported in 121 cases per 100,000 adults and 29 per 100,000 children in 2016. Various other factors supporting the market growth include rising expenditure in research and development for new therapies to treat uveitis as well as speedy approvals from U.S. FDA for the drugs in pipeline to treat the condition. However, factors such as irreversible blindness in some cases due to side effects of medications and other such medical conditions can thus, hinder the market growth for global uveitis treatment. The side effects associated with corticosteroids include high blood pressure, kidney damage, skin disorders, and others.
Rise in development of innovative biologics is expected to accelerate growth of the market
Primary driving factor contributing towards growth of the uveitis treatment market is rising incidence of uveitis. According to a study by American University of Beirut Medical Center in 2015, Uveitis is responsible for 10% of legal blindness in the U.S. and up to 25% of blindness in the developing countries. Moreover, according to a study conducted by F. I. Proctor Foundation, University of California, San Francisco in 2013 suggested that uveitis incidence rate among the U.S. population could be approximated to 24.9 cases per 100,000 people. In addition to this, several other factors driving growth of the market include rise in healthcare expenditure for treatment development and development of new and innovative biologics for uveitis treatment. However, factors limiting growth of the market include side effects such as kidney damage, high blood sugar, and osteoporosis due to immunosuppressant drugs. Moreover, complications associated with the medication could result in irreversible blindness, which is a major factor limiting the market growth.
Speedy FDA approvals for uveitis treatment drugs to propel the market growth
A large number of new as well as established companies are focusing on development of drugs for the treatment of uveitis in various forms such as monoclonal antibodies, immunosuppressant, corticosteroids, anti-fungal agents, anti-viral agents, and others. FDA is focusing on speedy drug approval process as uveitis has serious ill effects leading to disorders such as glaucoma and permanent blindness. This creates a highly conducive environment for market players to invest in research and development activities to file for patents as well as develop generic biologics for treating this disorder. According to the Regulatory Affairs Professionals Society, FDA has approved around 38 generic drugs till July 2017.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1094
Asia Pacific is expected to witness a significant growth in the global uveitis treatment market and this can be attributed to increasing number of regional players focusing on development of biologics for the treatment of uveitis. For instance, Santen Pharmaceuticals received U.S. FDA approval for its new drug in April 2017, for the treatment of non-infectious uveitis of the posterior segment.
Some of the major players operating in the uveitis treatment market are AbbVie, Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Santen Pharmaceuticals, Allergan Plc, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., and Alimera Sciences.
You may be interested
VanMoof Introduced Anti-Theft System for Smart BikesMohit Joshi - September 25, 2018
The company launched two new e-bikes models Electrified S2 and X2 with new theft protection features VanMoof, Dutch high-end bicycle manufacturer launched the Electrified S2 & X2…
Autoclave Market Analysis of Sales, Revenue, Share and Growth And Companies MELAG Medizintechnik oHG, Tuttnauer, Getinge AB, Belimed, SAKURA SEIKIAlbert R - September 25, 2018
According to a new market research study titled Autoclave Market to 2026 Global Analysis and Forecasts by Material Composition, Industries and End Products, The report highlights…
Optometry Equipment Market Emerging Trends,Forecasts 2018-2025 And Major Key Companies Canon, Carl Zeiss AG, Escalon Servicesc., Essilor International S.A., Haag-StreitAlex Mathew - September 25, 2018
According to a new market research study titled Optometry Equipment Market to 2026 Global Analysis and Forecasts by Material Composition, Industries and End Products, The report…